Tutor Qualification:Doctoral supervisor

Department:Department of pathophysiology

E-mail：chenxiaoy@mail.sysu.edu.cn

Research direction:The cellular and molecular mechanisms of mesenchymal stem cell therapy are dedicated to revealing the functional properties and damage repair mechanisms of mesenchymal stem cells, promoting their transformation and application, and providing new strategies for the treatment of refractory diseases such as graft-versus-host disease.

Personal Profile

Professor and Doctoral Supervisor at the Zhongshan School of Medicine, Sun Yat-sen University. Currently, he is a standing committee member of the Professional Committee of Stem Cells and Regenerative Medicine of the Guangdong Health Management Association and a standing committee member of the Precision Hematology Branch of the Guangdong Precision Medicine Application Society.

The main research direction focuses on the cellular and molecular mechanisms of mesenchymal stem cell therapy. He is committed to revealing the functional characteristics and injury repair mechanisms of mesenchymal stem cells, and promoting their translational applications, aiming to provide new strategies for the treatment of intractable diseases such as graft-versus-host disease. As the first author or corresponding author (including co-first author/co-corresponding author), he has published more than 10 academic papers in journals such as Leukemia, J Hematol Oncol, Theranostics, Mol Ther, and Cell Mol Immunol. As the drafter, he has formulated the group standard "Human Mesenchymal Stem Cells" (T/CSCB 0003-2021). His research achievements have won several awards, including the Young Scientists Award of the Chinese Medical Science and Technology Award in 2018, the First Prize of the Guangdong Natural Science Award in 2021, the First Prize of the Guangdong Medical Science and Technology Award in 2021, and the "Young Investigator Scientific Award" at the 27th International Congress of The Transplantation Society (TTS).

In recent years, he has undertaken projects such as the General Program of the National Natural Science Foundation of China and the Outstanding Young Scientists Fund Project of the Guangdong Natural Science Foundation. He/she has also participated in projects such as the National Key R & D Program and the Provincial Key Field R & D Program.

Publish Paper

  1. Liu J#, Lai X#, Bao Y#, Xie F, Li Z, Chen J, Li G, Wang T, Huang W, Ma Y, Shi J, Zhao E, Xiang AP*, Liu Q*, Chen X*. Intraperitoneally Delivered Mesenchymal Stem Cells Alleviate Experimental Colitis Through THBS1-Mediated Induction of IL-10-Competent Regulatory B Cells. Front Immunol. 2022, 13: 853894.
  2. Zhao K#, Lin R#, Fan Z#, Chen X#, Wang Y#, Huang F, Xu N, Zhang X, Zhang X, Xuan L, Wang S, Lin D, Deng L, Nie D, Weng J, Li Y, Zhang X, Li Y, Xiang AP*, Liu Q*. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.
  3. Chen X#, Huang J#, Wu J#, Hao J#, Fu B, Wang Y, Zhou B, Na T, Wei J, Zhang Y, Li Q, Hu S, Zhou J, Yu J, Wu Z, Zhu H, Cao J, Wang L, Peng Y, Liang L, Ma A*, Zhang Y*, Zhao T*, Xiang AP*. Human mesenchymal stem cells. Cell Prolif. 2022; 55(4): e13141.
  4. Wei Y#, Chen X#, Zhang H#, Su Q, Peng Y, Fu Q, Li J, Cao Y, Li X, Yang S, Ye Q, Huang H, Deng R, Li G, Xu B, Wu C, Wang J, Zhang X, Su X, Liu L*, Xiang P*, Wang C*. Efficacy and Safety of Bone Marrow-Derived Mesenchymal Stem Cells for Chronic Antibody-Mediated Rejection after Kidney Transplantation- A Single-arm, Two-dosing-regimen, Phase I/II Study. Front Immunol. 2021, 12: 662441.
  5. Liu Q#, Chen X#, Liu C#, Pan L, Kang X, Li Y, Du C, Dong S, Xiang AP*, Zhang Q*, Xu Y*. Mesenchymal Stem Cells Alleviate Experimental Immune-mediated Liver Injury via Chitinase 3-like protein 1-mediated T cell suppression. Cell Death Dis. 2021;12(3):240.
  6. Zheng S#, Huang K#, Xia W#, Shi J, Liu Q, Zhang X, Li G, Chen J, Wang T, Chen X*, Xiang AP. Mesenchymal stromal cells rapidly suppress TCR signaling-mediated cytokine transcription in activated T cells through the ICAM-1/CD43 interaction. Front Immunol. 2021, 12:609544.
  7. Liu J, Liu Q*, Chen X*. The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells. Front Immunol. 2020; 11:1843. 
  8. Chen X#, Cai C#, Xu D#, Liu Q, Zheng S, Liu L, Li G, Zhang X, Li X, Ma Y, Huang L, Chen J, Shi J, Du X, Xia W*, Xiang AP*, Peng Y*. Human mesenchymal stem cell-treated regulatory CD23+CD43+ B cells alleviate intestinal inflammation. Theranostics. 2019; 9(16): 4633-4647.
  9. Chen X#, Liu Q#, Xiang AP*. CD8+CD28- T cells: not only age-related cells but a subset of regulatory T cells. Cell Mol Immunol. 2018;15(8):734-736.
  10. Chen X#, Liu Q#, Huang W#, Cai C, Xia W, Peng Y, Zheng S, Li G, Xu Y, Wang J, Liu C, Zhang X, Huang L, Xiang AP*, Zhang Q*. Stanniocalcin-2 Contributes to Mesenchymal Stromal Cells Attenuating Murine Contact Hypersensitivity mainly via reducing CD8+ Tc1 Cells. Cell Death Dis. 2018; 9(5): 548.
  11. Zhang X#, Huang W#, Chen X#, Lian Y, Wang J, Cai C, Huang L, Wang T, Ren J*, Xiang AP*. CXCR5-overexpressing Mesenchymal Stromal Cells Exhibit Enhanced Homing and Can Decrease Contact Hypersensitivity. Mol ther. 2017;25(6):1434-1447.
  12. Peng Y#, Chen X#, Liu Q#, Zhang X, Huang K, Liu L, Li H, Zhou M, Huang F, Fan Z, Sun J, Liu Q, Ke M, Li X, Zhang Q, Xiang AP*. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10. Leukemia. 2015,29(3):636-46.
  13. Liu Q#, Zheng H#, Chen X#, Peng Y, Huang W, Li X, Li G, Xia W, Sun Q*, Xiang AP*. Human mesenchymal stromal cells enhance the immunomodulatory function of CD8+CD28- regulatory T cells. Cell Mol Immunol. 2015;12(6):708-18.
  14. Peng Y#, Chen X#, Liu Q#, Xu D, Zheng H, Liu L, Liu Q, Liu M, Fan Z, Sun J, Li X, Zou R, Xiang AP*. Alteration of Naive and Memory B-Cell Subset in Chronic Graft-Versus-Host Disease Patients After Treatment With Mesenchymal Stromal Cells. Stem Cells Transl Med. 2014,3(9):1023-31.

Research Projects

  • ​Guangdong Provincial Natural Science Foundation Outstanding Young Scientists Fund Project: Project No. 2023B1515020119, Duration: January 2023 - December 2026, Project Leader, In progress.
  • ​National Natural Science Foundation of China General Project: Project No. 82270230, Duration: January 2023 - December 2026, Project Leader, In progress.
  • ​National Key R & D Program: Project No. 2022YFA1105000, Duration: December 2022 - November 2027, Key Team Member, In progress.
  • ​National Natural Science Foundation of China General Project: Project No. 81970109, Duration: January 2020 - December 2023, Project Leader, In progress.
  • ​Guangzhou Pearl River Science and Technology Nova Special Project: Project No. 201906010095, Duration: April 2019 - March 2021, Project Leader, Completed.
  • ​Guangdong Provincial Key Field R & D Program Project: Project No. 2019B020236004, Duration: January 2019 - December 2021, Project Leader, Completed.
  • ​National Key R & D Program: Project No. 2017YFA0105500, Duration: July 2017 - December 2021, Key Team Member, Completed.
  • ​National Natural Science Foundation of China Youth Project: Project No. 81600102, Duration: January 2017 - December 2019, Project Leader, Completed.
  • ​Guangdong Provincial Science and Technology Plan Project (Public Welfare Research and Capacity Building): Project No. 2016A020214003, Duration: January 2016 - December 2018, Project Leader, Completed.

Awards and Honors

  • As the first author or corresponding author (including co-first author/co-corresponding author), more than 10 academic papers have been published in journals such as Leukemia, J Hematol Oncol, Theranostics, Mol Ther, and Cell Mol Immunol. Served as the drafter to formulate the group standard "Human Mesenchymal Stem Cells" (T/CSCB 0003-2021).
  • Research achievements have won several awards, including the Young Scientists Award of the Chinese Medical Science and Technology Award in 2018, the First Prize of the Guangdong Natural Science Award in 2021, the First Prize of the Guangdong Medical Science and Technology Award in 2021, and the "Young Investigator Scientific Award" at the 27th International Congress of The Transplantation Society (TTS).
  • In recent years, has undertaken projects such as the National Natural Science Foundation of China General Project and the Guangdong Provincial Natural Science Foundation Outstanding Young Scientists Fund Project. Participated in projects such as the National Key R & D Program and the Guangdong Provincial Key Field R & D Program.

Academic Part-time Positions

  • Standing Committee Member of the Professional Committee of Stem Cells and Regenerative Medicine, Guangdong Health Management Association.
  • Standing Committee Member of the Precision Hematology Branch of the Guangdong Precision Medicine Application Society.